The Michael Smith Laboratories, University of British Columbia, 301-2185 East Mall, Vancouver, V6T 1Z4, BC, Canada.
The Vancouver Prostate Centre, Vancouver Coastal Health Research Institute, Vancouver, Canada.
Sci Rep. 2018 Feb 13;8(1):2924. doi: 10.1038/s41598-018-20608-6.
Type 2 innate lymphoid cells (ILC2) potentiate immune responses, however, their role in mediating adaptive immunity in cancer has not been assessed. Here, we report that mice genetically lacking ILC2s have significantly increased tumour growth rates and conspicuously higher frequency of circulating tumour cells (CTCs) and resulting metastasis to distal organs. Our data support the model that IL-33 dependent tumour-infiltrating ILC2s are mobilized from the lungs and other tissues through chemoattraction to enter tumours, and subsequently mediate tumour immune-surveillance by cooperating with dendritic cells to promote adaptive cytolytic T cell responses. We conclude that ILC2s play a fundamental, yet hitherto undescribed role in enhancing anti-cancer immunity and controlling tumour metastasis.
2 型先天淋巴细胞 (ILC2) 增强免疫反应，然而，它们在癌症中调节适应性免疫的作用尚未得到评估。在这里，我们报告说，遗传缺乏 ILC2 的小鼠肿瘤生长速度明显加快，循环肿瘤细胞 (CTC) 的频率明显更高，导致转移到远端器官的情况也更为明显。我们的数据支持这样一种模型，即依赖于 IL-33 的肿瘤浸润性 ILC2 通过趋化作用从肺部和其他组织动员到肿瘤中，并随后通过与树突状细胞合作促进适应性细胞毒性 T 细胞反应来介导肿瘤免疫监视。我们得出结论，ILC2 在增强抗癌免疫和控制肿瘤转移方面发挥着基本但迄今为止尚未被描述的作用。
